...
首页> 外文期刊>Biocell >Microenvironment and related genes predict outcomes of patients with cervical cancer: evidence from TCGA and bioinformatic analysis
【24h】

Microenvironment and related genes predict outcomes of patients with cervical cancer: evidence from TCGA and bioinformatic analysis

机译:微环境和相关基因预测宫颈癌患者的结果:来自TCGA和生物信息分析的证据

获取原文

摘要

Cervical cancer (CESC) is one of the most common cancers and affects the female genital tract. Consistent HPV infection status has been determined to be a vital cause of tumorigenesis. HPV infection may induce changes to the immune system and limit the host’s immune response. Immunotherapy is therefore essential to improving the overall survival of both locally advanced and recurrent CESC patients. Using 304 relevant samples from TCGA, we assessed immune cell function in CESC patients to better understand the status of both tumor micro-environment cells and immune cells in CESC. Functional enrichment analysis, pathway enrichment analysis, and PPI network construction were performed to explore the differentially expressed genes (DEGs). The analysis identified 425 DEGs, which included 295 up-regulated genes and 130 down-regulated genes. We established that upregulation of CCL5 was correlated with significantly better survival, meaning that CCL5 expression could serve as a novel prognostic biomarker for CESC patients. We further focused on CCL5 as a hub gene in CESC, as it had significant correlations with increased numbers of several types of immune cells. Cell-type fractions of M1 macrophages were significantly higher in the high-immune-scores group, which was associated with better overall survival. Finally, we concluded that CCL5 is a promising prognostic biomarker for CESC, as well as a novel chemotherapeutic target.
机译:宫颈癌(CESC)是最常见的癌症之一,并影响女性生殖道。一致的HPV感染状态已被确定为肿瘤发生的重要原因。 HPV感染可能会导致免疫系统的变化并限制宿主的免疫应答。因此,免疫疗法对于提高局部先进和经常性CESC患者的整体存活至关重要。使用来自TCGA的304个相关样品,我们评估了CESC患者的免疫细胞功能,以更好地了解CESC中肿瘤微环境细胞和免疫细胞的状态。进行功能性富集分析,途径富集分析和PPI网络施工以探索差异表达基因(DEGS)。该分析鉴定了425℃,其中包括295个上调基因和130个下调基因。我们确定CCL5的上调与显着的存活率相关,这意味着CCL5表达可以作为CSC患者的新型预后生物标志物。我们进一步专注于CCL5作为CESC中的集线基因,因为它具有显着的相关性与若干类型的免疫细胞数量增加。高免疫分数组的M1巨噬细胞的细胞型分数显着高,这与更好的整体存活相关。最后,我们得出结论,CCL5是CCEC的一个有希望的预后生物标志物,以及一种新的化学治疗靶标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号